Celestica Inc. (TSE:CLS – Get Free Report) (NYSE:CLS)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of C$467.73 and traded as low as C$455.18. Celestica shares last traded at C$460.18, with a volume of 478,748 shares traded.
Analyst Ratings Changes
Several research firms recently commented on CLS. UBS Group upgraded shares of Celestica from a “hold” rating to a “buy” rating and set a C$430.00 price objective on the stock in a research report on Monday, August 24th. Scotiabank upgraded shares of Celestica to a “strong-buy” rating in a report on Tuesday, August 11th. Six research analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, Celestica has a consensus rating of “Strong Buy” and a consensus price target of C$388.33.
View Our Latest Report on Celestica
Celestica Trading Up 6.6%
Celestica (TSE:CLS – Get Free Report) (NYSE:CLS) last released its quarterly earnings results on Monday, July 27th. The company reported C$3.61 earnings per share for the quarter. Celestica had a return on equity of 50.28% and a net margin of 7.15%.The company had revenue of C$6.68 billion during the quarter. On average, analysts anticipate that Celestica Inc. will post 5.028804 EPS for the current year.
Celestica Company Profile
Celestica is a technology leader dedicated to driving customer success and market advancements. With deep expertise in design, engineering, manufacturing, supply chain, and platform solutions, Celestica enables critical data center infrastructure for AI, cloud and hybrid cloud, and advances technologies in high-growth markets. With a talented team and a strategic global network, Celestica helps its customers achieve competitive advantages.
See Also
- Five stocks we like better than Celestica
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Celestica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celestica and related companies with MarketBeat.com's FREE daily email newsletter.
